|
|
The future of effective aerosol therapies
lies in the optimization of drug-to-device and
device-to-drug.
PARI Pharma has taken the
next step and combined
formulation development,
next generation aerosol
platforms, and aerosol characterization under
one roof.
We are currently working on formulations
optimized to our Advanced Aerosol Delivery
platform - eFlow®.
This multifunctional development program is the
key to creating targeted therapies with high
deposition amounts, low side-effect profiles,
improved patient compliance…and happier,
healthier patients.
After 100 years, we know aerosol science
and aerosol delivery.
|
|
|
|
 |
| |
PARI Pharma
Completes Successful Clinical Trials for
Tobramycin 100 & Investigational eFlow for CF
[more]
- - - - - - - - - - - - - - - - -
PARI Pharma Unveils
Closed System Using eFlow Technologyat Medical Plastics
Conference [more]
- - - - - - - - - - - - - - - - -
Mpex Initiates a Phase 2 Clinical Trial of Aerosol
MP-376 in the Treatment of Chronic Bacterial Infections in
Cystic Fibrosis Patients
[more]
- - - - - - - - - - - - - - - - -
|
|
| |
|
